The partnership with Alnylam provides Tenaya with non-dilutive funding and significant optionality through milestone payments, reducing near-term cash burn concerns. Traders should monitor progress on target validation and any updates on milestone achievements, which could serve as future catalysts. Despite recent insider selling, the Alnylam collaboration de-risks Tenaya’s platform and validates its scientific approach, potentially attracting further partnerships or investor interest.
Price Chart
Executive Summary
Tenaya Therapeutics entered into a collaboration agreement with Alnylam Pharmaceuticals to discover and validate up to 15 novel gene targets for cardiovascular disease treatment. Tenaya will receive up to $10.0 million in upfront payments and is eligible for up to $1.13 billion in milestone payments based on development, regulatory, and sales achievements.
Key Financial Metrics
Key Facts
- Tenaya Therapeutics (TNYA) partnered with Alnylam Pharmaceuticals (ALNY) on a cardiovascular gene target discovery collaboration.
- The collaboration includes up to 15 gene targets, with a 24-month research phase during which both parties will conduct validation activities.
- Alnylam will pay Tenaya up to $10.0 million upfront, subject to reductions based on target advancement decisions.
- Tenaya is eligible to receive up to $1.13 billion in development, regulatory, and sales-based milestones for Company-nominated targets.
- Alnylam gains an exclusive, worldwide license to develop and commercialize products from validated targets.
- Alnylam may terminate the agreement at any time with notice, and the deal includes standard IP, confidentiality, and indemnification terms.
Financial Impact
Up to $10.0 million in near-term cash inflow and up to $1.13 billion in potential future milestone payments
Risk Factors
- Upfront payment is subject to reductions of $500,000 for up to eight targets not advanced, potentially reducing initial cash inflow to $6.0 million.
- Milestone payments are contingent on successful development, regulatory approval, and commercialization—many years away and subject to high failure rates.
- Alnylam can terminate the agreement unilaterally at any time, ending future payment potential.
- Tenaya is restricted from working on collaboration targets outside the agreement, limiting internal development flexibility.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-092654 |
| Document: 0001193125-26-092654-index-headers.html | 0001193125-26-092654 |
| Document: 0001193125-26-092654-index.html | 0001193125-26-092654 |
| Document: 0001193125-26-092654.txt | 0001193125-26-092654 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | DEFA14A | $0.3945 | awaiting T+60 | — | $0.4153 (+5.27%) |
Oct 23, 2026 3d ago | DEF 14A | $0.3850 | awaiting T+60 | — | $0.4153 (−7.87%) |
Aug 17, 2026 10w ago | 144 | $0.6990 | awaiting T+60 | — | $0.4153 (+40.59%) |
Jul 2, 2026 16w ago | 8-K | $0.7869 $0.5898 | ▼ −25.05% | ▼ −28.62% | $0.4153 (−47.22%) |
Jun 29, 2026 17w ago | 8-K | $0.7349 $0.6822 | ▼ −7.17% | ▼ −11.56% | $0.4153 (−43.49%) |
Jun 12, 2026 19w ago | Institutional Cluster | $0.7118 $0.6634 | ▲ +6.80% | ▲ +10.06% | $0.4153 (+41.65%) |
May 29, 2026 21w ago | 8-K | $0.8700 $0.7014 | ▼ −19.38% | ▼ −20.61% | $0.4153 (−52.26%) |
May 19, 2026 22w ago | Insider Cluster | $0.8080 $0.7281 | ▼ −9.89% | ▼ −14.89% | $0.4153 (−48.60%) |
Apr 16, 2026 27w ago | DEFA14A | $0.7470 $0.8365 | ▲ +11.98% | ▲ +4.94% | $0.4153 (−44.40%) |
Mar 11, 2026 32w ago | 8-K | $0.8930 $0.7280 | ▼ −18.48% | ▼ −29.17% | $0.4153 (−53.49%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers